Last reviewed · How we verify
Steroids switch
At a glance
| Generic name | Steroids switch |
|---|---|
| Sponsor | Centro Nacional de Investigaciones Oncologicas CARLOS III |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study in Adult Patients With Moderate to Severe Asthma (PHASE3)
- Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (PHASE2)
- A Study of Daratumumab (PHASE3)
- ISTH/ANRS 0409s INTEGRATE Lassa Fever Study (PHASE2, PHASE3)
- Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer (PHASE2)
- Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant (PHASE4)
- A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT (PHASE3)
- Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Steroids switch CI brief — competitive landscape report
- Steroids switch updates RSS · CI watch RSS
- Centro Nacional de Investigaciones Oncologicas CARLOS III portfolio CI